SS&C Technologies delivered a strong finish to 2025 with record Q4 adjusted revenue of $1.655 billion (up 8%) and adjusted diluted EPS of $1.69 (up 18%). The company achieved record adjusted EBITDA of $651 million, a 9% increase, with a margin expansion of 20 basis points to 39.3%. Full-year operating cash flow surged 26% to $1.745 billion, enabling the return of over $1 billion to shareholders via buybacks. Management expressed high confidence in 2026, guiding for approximately 5% organic revenue growth and 12% EPS growth, driven by 'lift out' mandates, AI integration, and the stability of recurring revenue in regulated markets.
| Metric | Value | Change |
|---|---|---|
| Q4 Adjusted Revenue | $1.655 billion | +8% |
| Q4 Adjusted EPS | $1.69 | +18% |
| Q4 Adjusted EBITDA | $651 million | +9% |
| Q4 Adjusted EBITDA Margin | 39.3% | +20 bps |
| FY 2025 Operating Cash Flow | $1.745 billion | +26% |
| FY 2025 Cash Flow per Share | $6.89 | +$1.42 |
| FY 2025 Share Repurchases | $1.04 billion | 12.3M shares |
| Net Leverage Ratio | 2.8x | N/A |
Management emphasized a significant shift in capital allocation strategy, prioritizing share repurchases over M&A. With over $1 billion allocated to buybacks in 2025 and a strengthened conviction at current price levels, SS&C signals confidence in its intrinsic value. This pivot suggests a focus on maximizing per-share earnings growth while remaining selective for only 'high-quality accretive acquisitions,' potentially indicating a view that the company is undervalued relative to its peers.
The company is positioning its proprietary data and code ownership as a competitive fortress against the rise of generic AI tools. By asserting that their 'mission-critical' software in regulated environments (SEC/CMS) is immune to the 'hallucinations' of public LLMs, SS&C is differentiating itself from fintech startups. This strategy aims to reassure investors that the AI boom is a tailwind rather than a disruption, allowing them to leverage AI for efficiency without risking client regulatory compliance.
SS&C is driving growth through complex 'lift out' mandates, such as Insignia and Humana, which involve outsourcing entire accounting operations. These deals create multi-year partnerships with recurring revenue that scales over time. Management highlighted that these wins are repeatable across regions and business lines, providing visibility into future organic growth and validating the stickiness of their platform model.
The integration of the Callisto acquisition and the migration of Morningstar clients onto the Black Diamond platform are key strategic priorities. Management noted 'strong engagement' and 'strategically meaningful' projects going live post-acquisition. This indicates successful execution on M&A integration and cross-selling opportunities, which supports the 5%+ organic growth targets for 2026.
Despite short-term lumpiness, management remains committed to the healthcare sector, citing it as an 'enormous market' with long-term potential. The development of 'Amesys' and 'One Health' platforms suggests a strategic pivot toward integrated medical and pharmacy solutions. While the Elevance relationship faces headwinds, the focus on new technology implies a strategic bet on modernizing legacy healthcare systems to drive future growth.
The healthcare segment experienced a 'tough quarter' from an organic perspective during its seasonally strongest period. Management admitted growth is 'lumpy' and that they would 'prefer to have more growth.' This indicates potential execution challenges or market headwinds in a segment that is supposed to be a long-term growth driver, raising concerns about the reliability of this revenue stream.
The Intelligent Automation business (including Blue Prism) appears to be facing headwinds, with management noting 'delays in decision-making' impacting growth. While they are optimistic for 2026, the comparison to a 'really large license in Q4 the year before' suggests volatility in demand for automation tools, which could be sensitive to client budget cycles.
The relationship with Elevance remains uncertain, with management acknowledging the original sponsor has moved on and relationships are 'difficult to break.' While they see 'rays of sunshine,' the lack of a firm timeline for onboarding Dominion Rx represents a lingering overhang on the healthcare narrative and potential revenue upside.
There was a likely transcription error in the full-year 2026 revenue guidance range ('$6.654 billion to $6.14 billion'), where the lower bound exceeds the upper bound in the text. While the organic growth target of 5.1% provides clarity, the verbal slip or transcript error introduces a minor element of communication sloppiness or confusion regarding the absolute revenue numbers.
Overall: Management exhibited a highly confident and assured demeanor throughout the call. Bill Stone, in particular, was dismissive of competitive threats from AI startups, emphasizing SS&C's 'deep moat' and regulatory protections. The tone shifted from defensive regarding healthcare headwinds to emphatic when discussing capital allocation and the company's technological advantages.
Confidence: HIGH - Management provided specific 2026 guidance, highlighted record cash flow metrics, and spoke with conviction about their AI strategy and the integration of recent acquisitions. The commitment to aggressive share repurchases further underscores their confidence in cash generation.
$6.654 billion to $6.14 billion (Note: Transcript text order likely reversed, implies ~5.1% organic growth)
$6.70 to $7.02 (~12% growth at midpoint)
$1.608 billion to $1.648 billion
$1.62 to $1.68
40% in Q4
Hedging & Uncertainty: Management used specific qualifiers to temper expectations around the healthcare and automation segments, describing them as 'lumpy' and subject to 'delays in decision-making.' However, hedging was minimal regarding the core financial performance and capital allocation. Phrases like 'we strongly believe,' 'we will prioritize,' and 'we expect' were used frequently to express high certainty. The use of 'rays of sunshine' regarding Elevance suggests a cautious, non-committal optimism rather than a guaranteed outcome.
"We take all competitors seriously, but we strongly believe we have a deep moat not easily navigated." - Bill Stone, CEO
"At current levels, our conviction around share repurchase has strengthened, and we will prioritize repurchases absent high-quality accretive acquisitions." - Bill Stone, CEO
"Large language models sometimes have hallucinations... those regulators, they don't really quite understand us telling us. A hallucination." - Bill Stone, CEO
"We think that healthcare is a long-term play, and, you know, trying to go quarter to quarter or even year to year is a tough comp." - Bill Stone, CEO
"We're uniquely positioned and structurally protected through the ownership of our software and code..." - Bill Stone, CEO
"We have the financial wherewithal to invest very, very wisely." - Bill Stone, CEO
Analyst Sentiment: Analysts focused heavily on the underperformance of the healthcare segment and the sustainability of growth in the Intelligent Automation unit. There was also significant interest in the M&A landscape and the company's competitive positioning against AI-driven fintechs.
Management Responses: Bill Stone handled the majority of the Q&A, providing detailed and sometimes colorful defenses of the company's moat. He was direct about the lumpiness in healthcare but reframed it as a long-term opportunity. He dismissed AI competitors by highlighting regulatory barriers and the complexity of SS&C's operations.
Healthcare segment organic weakness and seasonality.
Update on the Elevance relationship and Dominion Rx onboarding.
Growth drivers in Alternative Administration and Assets Under Administration (AuA).
Performance and outlook for the Intelligent Automation (Blue Prism) business.
Competitive advantages regarding AI and Large Language Models (LLMs).
M&A appetite and capital allocation priorities.
SS&C Technologies presents a compelling investment case driven by its robust financial performance and shareholder-friendly capital allocation. The company's 18% EPS growth and 26% cash flow growth in 2025 demonstrate strong operational leverage. Management's pivot to aggressive share repurchases, funded by record cash flows, provides a solid floor for the stock. The 'deep moat' argument is credible; regulated financial clients cannot easily switch to generic AI tools due to compliance risks, positioning SS&C to monetize AI internally rather than being disrupted by it. While healthcare headwinds are a near-term drag, the core GIDS and Wealth Management businesses are accelerating. The 2026 guidance for double-digit EPS growth and margin expansion supports a positive outlook.
Management views strict regulation (SEC, CMS) as a competitive advantage, as it prevents clients from adopting 'hallucinating' generic AI tools, thereby protecting SS&C's market share.
The company observes that competitors may be under 'different pressures,' potentially creating acquisition opportunities, but notes that asking prices remain a factor.
Guidance assumes short-term interest rates will remain at current levels, with net interest expense expected to be consistent year-over-year.